Regeneron Pharmaceuticals Inc (REGN) |
|
Regeneron Pharmaceuticals Inc Balance Sheet Annual
REGN
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
REGN Balance Sheets
(Annual, GAAP in millions $) |
(Dec 31 2023) 2023 |
(Dec 31 2022) 2022 |
(Dec 31 2021) 2021 |
(Dec 31 2020) 2020 |
(Dec 31 2019) 2019 |
ASSETS |
Cash & cash equivalent |
2,730.00 |
3,105.90 |
2,885.60 |
2,193.70 |
1,617.80 |
Cash, Cash Eqvivalents Other |
- |
- |
- |
- |
- |
Marketable Securities, Current SH |
8,114.80 |
4,636.40 |
2,809.10 |
1,393.30 |
1,596.50 |
Cash
& Short-term Investments |
10,844.80 |
7,742.30 |
5,694.70 |
3,587.00 |
3,214.30 |
Accounts receivable |
5,667.30 |
5,328.70 |
6,036.50 |
404.70 |
311.60 |
Accounts Receivable, Related Parties, Current |
- |
- |
- |
- |
260.60 |
Notes Receivable, Current |
- |
- |
- |
- |
- |
Inventories |
2,580.50 |
2,401.90 |
1,951.30 |
1,916.60 |
1,415.50 |
Other Current Assets |
- |
0.00 |
0.00 |
3,710.00 |
2,100.00 |
Prepaid Expense And Other Assets Current |
386.60 |
411.20 |
332.40 |
160.80 |
387.10 |
Total Current Assets |
19,479.20 |
15,884.10 |
14,014.90 |
9,779.10 |
7,689.10 |
Equipment/Property/Plant Net |
- |
- |
- |
- |
- |
Goodwill net |
- |
- |
- |
- |
- |
Intangible Assets |
1,038.60 |
915.50 |
- |
- |
- |
Long-term investments |
5,396.50 |
6,591.80 |
6,838.00 |
3,135.60 |
3,256.80 |
Accounts Receivable, Net, Noncurrent |
- |
- |
- |
- |
- |
Financial Instruments |
- |
- |
- |
- |
- |
Deferred Tax Assets, Net, Noncurrent AS |
- |
- |
- |
- |
- |
Other Assets, Noncurrent |
4,592.00 |
4,101.00 |
3,706.00 |
3,391.00 |
3,036.00 |
Deferred, Prepaid and Other Assets, Noncurrent |
- |
- |
- |
- |
- |
Discontinued operations, Noncurrent |
- |
- |
- |
- |
- |
Deferred Income Tax Assets Net |
2,575.40 |
1,723.70 |
876.90 |
858.90 |
824.20 |
Total Assets |
33,080.20 |
29,214.50 |
25,434.80 |
17,163.30 |
14,805.20 |
LIABILITIES |
Accounts Payable, Current AC |
606.60 |
589.20 |
564.00 |
475.50 |
418.10 |
Accrued Liabilities And Other Liabilities |
2,357.90 |
2,074.20 |
2,206.80 |
1,521.80 |
1,086.80 |
Financial Instruments |
- |
- |
- |
- |
- |
Short-term Debt DE1 |
- |
- |
- |
- |
- |
Other Liabilities, Current |
- |
0.00 |
- |
700.10 |
591.70 |
Taxes Payable |
- |
- |
- |
- |
- |
Deferred Revenue, Current DE |
- |
- |
- |
- |
- |
Discontinued Operation, Liabilities, Current |
- |
- |
- |
- |
- |
Deferred Revenue From Related Party Current |
- |
- |
719.70 |
- |
- |
Deferred Revenue Other Current |
458.90 |
477.90 |
442.00 |
- |
- |
Facility Lease Obligations Current |
- |
- |
- |
- |
- |
Total Current Liabilities |
3,423.40 |
3,141.30 |
3,932.50 |
2,697.40 |
2,096.60 |
Long-term debt |
1,982.90 |
1,981.40 |
1,980.00 |
1,978.50 |
- |
Capital Lease and Other |
- |
- |
- |
- |
- |
Convertible Notes Payable, Noncurrent LO |
- |
- |
- |
- |
- |
Total
Long-term Debt |
1,982.90 |
1,981.40 |
1,980.00 |
1,978.50 |
- |
Financial Instruments, Insurance, Noncurrent |
- |
- |
- |
- |
- |
Employee Benefit Plans, Noncurrent |
- |
- |
- |
- |
- |
Deferred Revenue, Noncurrent DE |
- |
- |
- |
- |
- |
Accrued Income Taxes, Noncurrent |
- |
- |
- |
- |
- |
Discontinued Operation, Liabilities, Noncurrent |
- |
- |
- |
- |
- |
Other liabilities, Noncurrent |
854.10 |
638.00 |
680.20 |
1,462.10 |
1,618.90 |
Total Liabilities |
7,107.10 |
6,550.50 |
6,666.00 |
6,138.00 |
3,715.50 |
SHAREHOLDER'S EQUITY |
|
-12,560.40 |
- |
- |
- |
- |
Common Stock Value |
1.80 |
1.80 |
- |
- |
- |
Treasury Stock Value |
- |
- |
-8,260.90 |
-6,613.30 |
-739.90 |
Additional Paid In Capital Common Stock |
11,354.00 |
9,949.30 |
8,087.50 |
6,716.20 |
4,428.60 |
Retained Earnings / Accumulated Deficit |
27,260.30 |
23,306.70 |
18,968.30 |
10,893.00 |
7,379.80 |
Other Equity |
-82.60 |
-10,593.80 |
-26.10 |
29.40 |
21.20 |
Noncontrolling interests & other |
- |
- |
- |
- |
- |
Total
Stockholder's Equity |
25,973.10 |
22,664.00 |
18,768.80 |
11,025.30 |
11,089.70 |
Liabilities & Stockholder's
Equity |
33,080.20 |
29,214.50 |
25,434.80 |
17,163.30 |
14,805.20 |
|
|